Caffeine + Dextromethorphan + Enzalutamide + Enzalutamide Placebo to Match (PTM)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacokinetics of Dextromethorphan
Conditions
Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine, Prostate Cancer
Trial Timeline
Oct 2, 2013 → Feb 3, 2014
NCT ID
NCT02225093About Caffeine + Dextromethorphan + Enzalutamide + Enzalutamide Placebo to Match (PTM)
Caffeine + Dextromethorphan + Enzalutamide + Enzalutamide Placebo to Match (PTM) is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics of Dextromethorphan. The current trial status is completed. This product is registered under clinical trial identifier NCT02225093. Target conditions include Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine, Prostate Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02225093 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics of Dextromethorphan